DSMB


Also found in: Acronyms.

DSMB

Data & Safety Monitoring Board Clinical research A committee of independent clinical research experts who review data in ongoing clinical trials, ensuring that participants are not exposed to undue risk, and look for any differences in effectiveness between experimental and control groups. See Clinical research.

data safety monitoring board

, data and safety monitoring board,

DSMB

An independent group of scientists and concerned community members who oversee the interim findings of a research project to determine whether the research undertaken is proceeding without evidence of harm to the subjects enrolled in the study.
References in periodicals archive ?
BrainStorm's CEO, Chaim Lebovits, commented "We are pleased that the DSMB has again identified no concerns following their review of the safety data accumulated for the NurOwn[sup.
The members of the DSMB approved unanimously the continuation of the trial having concluded that one month post treatment, C-Cure and C-Cathez shows no safety issue that compromises the continuation of the CHART-1 Phase III study.
John Dawson, Chief Executive Officer of Oxford BioMedica, said: "The continued progress of our ophthalmology portfolio, supported by another positive DSMB review, is encouraging - particularly given that early RetinoStat[sup.
It is crucial that all members of the research team understand the role and responsibilities of the DSMB when conducting clinical research.
BrainStorm's CEO, Tony Fiorino, MD, PhD, commented "We are gratified that the DSMB has found no concerns after having reviewed the safety data accumulated for the study through January.
The DSMB reviewed mortality and other safety data from the first 21 patients enrolled in this single-center trial at Johannesburg Hospital Trauma Unit in South Africa.
The DSMB advised YM that there were no safety concerns and that the trial
7] Due to the dispute with the company, the study leadership was unable to obtain the final data, and published from the data submitted to the DSMB, with updates during the summer of 1999.
Additionally, the DSMB has authorized the Company to treat all three patients in the second cohort of its European trial for SMD.
In the news release, BrainStorm Announces Positive DSMB Recommendation in Ongoing Phase 2 Trial with NurOwn(TM) in ALS, issued Feb.
The DSMB will meet again this summer to review both safety and mortality trends when the results from the first 50 percent of enrolled patients have been analyzed.
The DSMB determined that the patients from the first dosing cohort were clear of any significant treatment-related adverse events.